Zebra Biologics is developing bio‑superior antibody therapeutics and complex biologic targets using technology developed by Dr. Richard Lerner at The Scripps Research Institute in San Diego. Its platform reportedly selects antibodies for function rather than simple binding and is described by OPKO Health as an advanced version of a core technology that contributed to discovery of Humira. The company has a preclinical pipeline of candidate antibodies targeting diabetes and obesity, oncology, and neurological disease. Zebra plans to enter R&D collaborations with pharma and biotech partners to advance a portfolio of bio‑superiors into clinical development within the next five years. Founded this summer and based in Concord, Mass., the company is led by Ronald Lindsay, an executive vice president at Sequenom Inc. Financially, Zebra disclosed in an SEC filing that it raised $9 million in its first investment round from four investors; OPKO Health said it was making an undisclosed strategic investment.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2013